250 related articles for article (PubMed ID: 16814438)
1. Risk assessment for coenzyme Q10 (Ubiquinone).
Hathcock JN; Shao A
Regul Toxicol Pharmacol; 2006 Aug; 45(3):282-8. PubMed ID: 16814438
[TBL] [Abstract][Full Text] [Related]
2. Risk assessment for carnitine.
Hathcock JN; Shao A
Regul Toxicol Pharmacol; 2006 Oct; 46(1):23-8. PubMed ID: 16901595
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment for the carotenoids lutein and lycopene.
Shao A; Hathcock JN
Regul Toxicol Pharmacol; 2006 Aug; 45(3):289-98. PubMed ID: 16814439
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment for creatine monohydrate.
Shao A; Hathcock JN
Regul Toxicol Pharmacol; 2006 Aug; 45(3):242-51. PubMed ID: 16814437
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment for glucosamine and chondroitin sulfate.
Hathcock JN; Shao A
Regul Toxicol Pharmacol; 2007 Feb; 47(1):78-83. PubMed ID: 16942821
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment for the amino acids taurine, L-glutamine and L-arginine.
Shao A; Hathcock JN
Regul Toxicol Pharmacol; 2008 Apr; 50(3):376-99. PubMed ID: 18325648
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial.
Ikematsu H; Nakamura K; Harashima S; Fujii K; Fukutomi N
Regul Toxicol Pharmacol; 2006 Apr; 44(3):212-8. PubMed ID: 16431002
[TBL] [Abstract][Full Text] [Related]
8. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system.
Liu ZX; Artmann C
Altern Ther Health Med; 2009; 15(2):42-6. PubMed ID: 19284181
[TBL] [Abstract][Full Text] [Related]
10. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations.
Bhagavan HN; Chopra RK
Mitochondrion; 2007 Jun; 7 Suppl():S78-88. PubMed ID: 17482886
[TBL] [Abstract][Full Text] [Related]
11. Safety assessment of coenzyme Q10 (CoQ10).
Hidaka T; Fujii K; Funahashi I; Fukutomi N; Hosoe K
Biofactors; 2008; 32(1-4):199-208. PubMed ID: 19096117
[TBL] [Abstract][Full Text] [Related]
12. Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy individuals: a double-blind, randomized controlled trial.
Shah SA; Sander S; Cios D; Lipeika J; Kluger J; White CM
Ann Pharmacother; 2007 Mar; 41(3):420-5. PubMed ID: 17341532
[TBL] [Abstract][Full Text] [Related]
13. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.
Levy G; Kaufmann P; Buchsbaum R; Montes J; Barsdorf A; Arbing R; Battista V; Zhou X; Mitsumoto H; Levin B; Thompson JL
Neurology; 2006 Mar; 66(5):660-3. PubMed ID: 16534103
[TBL] [Abstract][Full Text] [Related]
14. [Protective effects of coenzyme Q10 on the adverse reactions of anthracycline antibiotics: using double blind method--with special reference to hair loss].
Akihama T; Nakamoto Y; Shindo T; Nakayama Y; Miura A
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2125-9. PubMed ID: 6354099
[TBL] [Abstract][Full Text] [Related]
15. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure.
Sander S; Coleman CI; Patel AA; Kluger J; White CM
J Card Fail; 2006 Aug; 12(6):464-72. PubMed ID: 16911914
[TBL] [Abstract][Full Text] [Related]
16. The role of coenzyme Q10 in heart failure.
Weant KA; Smith KM
Ann Pharmacother; 2005 Sep; 39(9):1522-6. PubMed ID: 16046484
[TBL] [Abstract][Full Text] [Related]
17. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
Ferrante KL; Shefner J; Zhang H; Betensky R; O'Brien M; Yu H; Fantasia M; Taft J; Beal MF; Traynor B; Newhall K; Donofrio P; Caress J; Ashburn C; Freiberg B; O'Neill C; Paladenech C; Walker T; Pestronk A; Abrams B; Florence J; Renna R; Schierbecker J; Malkus B; Cudkowicz M
Neurology; 2005 Dec; 65(11):1834-6. PubMed ID: 16344537
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
[TBL] [Abstract][Full Text] [Related]
19. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.
Shults CW; Flint Beal M; Song D; Fontaine D
Exp Neurol; 2004 Aug; 188(2):491-4. PubMed ID: 15246848
[TBL] [Abstract][Full Text] [Related]
20. Considerations for supplementing with coenzyme Q10 during statin therapy.
Levy HB; Kohlhaas HK
Ann Pharmacother; 2006 Feb; 40(2):290-4. PubMed ID: 16449543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
